Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with huntington's disease

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Huang, Yen Chu ^a   Wu, Yih Ru ^a   Tseng, Mu Yun ^a   Chen, Yi Chun ^a   Hsieh, Sen Yung ^b   Chen, Chiung Mei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A6; HAPTOGLOBIN; PROTEOME; PROTHROMBIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN A-IV; APOLIPOPROTEIN A4; BIOLOGICAL MARKER;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROTEIN INTERACTION; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; CASE CONTROL STUDY; CEREBROSPINAL FLUID; METHODOLOGY; PROTEOMICS;

APOLIPOPROTEINS A; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HAPTOGLOBINS; HUMANS; HUNTINGTON DISEASE; PROTEOMICS; PROTHROMBIN;

EID: 79551623131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015809     Document Type: Article

References (47)

1. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983.
2. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
3. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, et al. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448: 704-708.
4. Anderson AN, Roncaroli F, Hodges A, Deprez M, Turkheimer FE (2008) Chromosomal profiles of gene expression in Huntington's disease. Brain 131: 381-388.
5. Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 27: 7899-7910.
6. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, et al. (2006) Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129: 877-886.
7. Djoussé L, Knowlton B, Cupples LA, Marder K, Shoulson I, et al. (2002) Weight loss in early stage of Huntington's disease. Neurology 59: 1325-1330.
8. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, et al. (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Commun 359: 335-340.
9. Saft C, Zange J, Andrich, Müller K, Lindenberg K, et al. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 20: 674-679.
10. Roze E, Saudou F, Caboche J (2008) Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 21: 497-503.
11. Strehlow AN, Li JZ, Myers RM (2007) Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space. Hum Mol Genet 16: 391-409.
12. Fang Q, Strand A, Law W, Faca VM, Fitzgibbon MP, et al. (2009) Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 8: 451-466.
13. Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, et al. (2001) N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J Neurochem 79: 1109-1112.
14. Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJ (2008) Increased levels of gamma-glutamylamines in Huntington disease CSF. J Neurochem 106: 37-44.
15. Nemes Z, Fésüs L, Égerházi A, Keszthelyi A, Degrell IM (2001) N(epsilon)(- gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia. Neurobiol Aging 22: 403-406.
16. Sárvári M, Fésüs L, Nemes Z (2002) Transglutaminase-mediated crosslinking of neural proteins in Alzheimer's disease and other primary dementias. Drug Develop Res 56: 458-472.
17. Montine TJ, Beal MF, Robertson D, Cudkowicz ME, Biaggioni I, et al. (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52: 1104-1105.
18. Björkqvist M, Leavitt BR, Nielsen JE, Landwehrmeyer B, Ecker D, et al. (2007) Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov Disord 22: 1952-1954.
19. Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord 15: 245-8.
20. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205: 1869-1877.
21. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, et al. (2007) Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6: 2833-2840.
22. Huntington Study Group (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11: 136-142.
23. Taneda H, Andoh K, Nishioka J, Takeya H, Suzuki K (1994) Blood coagulation factor Xa interacts with a linear sequence of the kringle 2 domain of prothrombin. J Biochem 116: 589-597.
24. Mann KG (1999) Biochemistry and physiology of blood coagulation. Thromb Haemost 82: 165-174.
25. Sokolova E, Reiser G (2008) Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 100: 576-581.
26. Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL (2006) Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 65: 19-25.
27. Luo W, Wang Y, Reiser G (2007) Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 56: 331-345.
28. Suo Z, Wu M, Ameenuddin S, Anderson HE, Zoloty JE, et al. (2002) Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem 80: 655-666.
29. Wang H, Ubl JJ, Stricker R, Reiser G (2002) Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. Am J Physiol Cell Physiol 283: C1351-C1364.
30. Won SY, Choi SH, Jin BK (2009) Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: role of microglial NADPH oxidase. J Neuroimmunol 214: 83-92.
31. Choi SH, Joe EH, Kim SU, Jin BK (2003) Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J Neurosci 23: 5877-5886.
32. Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, et al. (2005) Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 95: 1755-1765.
33. Choi SH, Lee DY, Ryu JK, Kim J, Joe EH, et al. (2003) Thrombin induces nigral dopaminergic neurodegeneration in vivo by altering expression of deathrelated proteins. Neurobiol Dis 14: 181-193.
34. Hsiao HY, Chern Y (2010) Targeting Glial Cells to Elucidate the Pathogenesis of Huntington's Disease. Mol Neurobiol 14: 248-255.
35. Shen L, Pearson KJ, Xiong Y, Lo CM, Tso P, et al. (2008) Characterization of apolipoprotein A-IV in brain areas involved in energy homeostasis. Physiol Behav 95: 161-167.
36. Shen L, Tso P, Woods SC, Sakai RR, Davidson WS, et al. (2007) Hypothalamic apolipoprotein A-IV is regulated by leptin. Endocrinology 148: 2681-2689.
37. Tso P, Liu M, Kalogeris TJ, Thomson AB (2001) The role of apolipoprotein AIV in the regulation of food intake. Annu Rev Nutr 21: 231-254.
38. Fujimoto K, Fukagawa K, Sakata T, Tso P (1993) Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 91: 1830-1833.
39. Carter K, Worwood M (2007) Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 29: 92-110.
40. Zhao X, Song S, Sun G, Strong R, Zhang J, et al. (2009) Neuroprotective role of haptoglobin after intracerebral hemorrhage. J Neurosci 29: 15819-15827.
41. Lee MY, Kim SY, Choi JS, Lee IH, Choi YS, et al. (2002) Upregulation of haptoglobin in reactive astrocytes after transient forebrain ischemia in rats. J Cereb Blood Flow Metab 22: 1176-1180.
42. Conti A, Sanchez-Ruiz Y, Bachi A, Beretta L, Grandi E, et al. (2004) Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. J Neurotraum 21: 854-863.
43. Chang KH, Lyu RK, Tseng MY, Ro LS, Wu YR, et al. (2007) Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barre Syndrome revealed by proteomics analysis. Proteomics - Clin Appl 1: 467-475.
44. Pantoni L, Inzitari D (1995) Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer's disease patients. Acta Neurol Scand 91: 225.
45. Li X, Miyajima M, Mineki R, Taka H, Murayama K, et al. (2006) Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir (Wien) 148: 859-864.
46. Bai S, Liu S, Guo X, Qin Z, Wang B, et al. (2010) Proteome analysis of haptoglobin in cerebrospinal fluid of neuromyelitis optica. Mol Biol Rep 37: 1619-1625.
47. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EFr, et al. (2004) An investigation into the human serum "interactome". Electrophoresis 25: 1289-1298.